Search

Your search keyword '"Agha, Mounzer"' showing total 195 results
Start Over Author "Agha, Mounzer" Publication Type Academic Journals
195 results on '"Agha, Mounzer"'

3. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study

Author

Martin, Thomas, Lin, Yi, Agha, Mounzer, Cohen, Adam D, Htut, Myo, Stewart, A Keith, Hari, Parameswaran, Berdeja, Jesus G, Usmani, Saad Z, Yeh, Tzu-Min, Olyslager, Yunsi, Goldberg, Jenna D, Schecter, Jordan M, Madduri, Deepu, Jackson, Carolyn C, Deraedt, William, Gries, Katharine S, Fastenau, John M, Trudeau, Jeremiah J, Akram, Muhammad, Pacaud, Lida, Jakubowiak, Andrzej, and Jagannath, Sundar

Published
2022
Full Text
View/download PDF

8. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Author

Berdeja, Jesus G, Madduri, Deepu, Usmani, Saad Z, Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam D, Stewart, A Keith, Hari, Parameswaran, Htut, Myo, Lesokhin, Alexander, Deol, Abhinav, Munshi, Nikhil C, O'Donnell, Elizabeth, Avigan, David, Singh, Indrajeet, Zudaire, Enrique, Yeh, Tzu-Min, Allred, Alicia J, Olyslager, Yunsi, Banerjee, Arnob, Jackson, Carolyn C, Goldberg, Jenna D, Schecter, Jordan M, Deraedt, William, Zhuang, Sen Hong, Infante, Jeffrey, Geng, Dong, Wu, Xiaoling, Carrasco-Alfonso, Marlene J, Akram, Muhammad, Hossain, Farah, Rizvi, Syed, Fan, Frank, Lin, Yi, Martin, Thomas, and Jagannath, Sundar

Published
2021
Full Text
View/download PDF

10. MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT)

Author

Hillengass, Jens, Cohen, Adam D, Delforge, Michel, Einsele, Hermann, Goldschmidt, Hartmut, Weisel, Katja, Raab, Marc-Steffen, Scheid, Christof, Schecter, Jordan M, de Braganca, Kevin C, Varsos, Helen, Yeh, Tzu-min, Mistry, Pankaj, Roccia, Tito, Corsale, Christina, Akram, Muhammad, Pacaud, Lida, Nesheiwat, Tonia, Agha, Mounzer, and Cohen, Yael C

Published
2022
Full Text
View/download PDF

11. MM-181 CARTITUDE-1: Two-Year Post Last Patient in (LPI) Results From the Phase 1b/2 Study of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Usmani, Saad Z, Martin, Thomas, Berdeja, Jesus G, Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam D, Deol, Abhinav, Htut, Myo, Lesokhin, Alexander, Munshi, Nikhil C, O'Donnell, Elizabeth, Jackson, Carolyn C, Yeh, Tzu-min, Banerjee, Arnob, Zudaire, Enrique, Madduri, Deepu, Zhou, Changwei, Pacaud, Lida, Lin, Yi, and Jagannath, Sundar

Published
2022
Full Text
View/download PDF

12. MM-153 Phase 2 CARTITUDE-2 Study (Cohort B): Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients With Multiple Myeloma (MM) and Early Relapse After Initial Therapy

Author

Agha, Mounzer, Van de Donk, Niels WCJ, Cohen, Adam D, Cohen, Yael C, Anguille, Sébastien, Kerre, Tessa, Roeloffzen, Wilfried, Schecter, Jordan M, de Braganca, Kevin C, Varsos, Helen, Mistry, Pankaj, Roccia, Tito, Zudaire, Enrique, Corsale, Christina, Akram, Muhammed, Geng, Dong, Nesheiwat, Tonia, Pacaud, Lida, Sonneveld, Pieter, and Zweegman, Sonja

Published
2022
Full Text
View/download PDF

14. Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia

Author

Boyiadzis, Michael, Agha, Mounzer, Redner, Robert L., Sehgal, Alison, Im, Annie, Hou, Jing-Zhou, Farah, Rafic, Dorritie, Kathleen A., Raptis, Anastasios, Lim, Seah H., Wang, Hong, Lapteva, Natalia, Mei, Zhuyong, Butterfield, Lisa H., Rooney, Cliona M., and Whiteside, Theresa L.

Published
2017
Full Text
View/download PDF

16. Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients.

Author

Haidar, Ghady, Jacobs, Jana L, Kramer, Kailey Hughes, Naqvi, Asma, Heaps, Amy, Parikh, Urvi, McCormick, Kevin D, Sobolewski, Michele D, Agha, Mounzer, Bogdanovich, Tatiana, Bushunow, Vasilii, Farah, Rafic, Hensley, Matthew, Hsu, Yen-Michael S, Johnson, Bruce, Klamar-Blain, Cynthia, Kozar, Jennifer, Lendermon, Elizabeth, Macatangay, Bernard J C, and Marino, Christopher C

Subjects
COVID-19, HOMOGRAFTS, IMMUNOCOMPROMISED patients, RNA, INVESTIGATIONAL drugs, ANTIVIRAL agents, TREATMENT effectiveness, CELLS, DESCRIPTIVE statistics, T cells
Abstract

We administered severe acute respiratory syndrome coronavirus-2 viral-specific T cells (VSTs) under emergency investigational new drug applications to 6 immunocompromised patients with persistent coronavirus disease 2019 (COVID-19) and characterized clinical and virologic responses. Three patients had partial responses after failing other therapies but then died. Two patients completely recovered, but the role of VSTs in recovery was unclear due to concomitant use of other antivirals. One patient had not responded to 2 courses of remdesivir and experienced sustained recovery after VST administration. The use of VSTs in immunocompromised patients with persistent COVID-19 requires further study. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. MM-505 Efficacy and Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma With Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohort D

Author

Arnulf, Bertrand, Kerre, Tessa, Agha, Mounzer, Delforge, Michel, Braunschweig, Ira, Shah, Nishi, Richard, Shambavi, Alsina, Melissa, Einsele, Hermann, Mistry, Pankaj, Varsos, Helen, Corsale, Christina, Schecter, Jordan, De Braganca, Kevin, Jethava, Yogesh, Song, Qingxuan, Koneru, Mythili, Akram, Muhammad, Cohen, Yaël, and Roeloffzen, Wilfried

Published
2024
Full Text
View/download PDF

19. Efficacy and Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma With Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohort D

Author

Arnulf, Bertrand, Kerre, Tessa, Agha, Mounzer, Delforge, Michel, Braunschweig, Ira, Shah, Nishi, Richard, Shambavi, Alsina, Melissa, Einsele, Hermann, Mistry, Pankaj, Varsos, Helen, Corsale, Christina, Schecter, Jordan, De Braganca, Kevin, Jethava, Yogesh, Song, Qingxuan, Koneru, Mythili, Akram, Muhammad, Cohen, Yaël, and Roeloffzen, Wilfried

Published
2024
Full Text
View/download PDF

21. Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Author

Hassoun, Hani, Jacobus, Susanna J., Richardson, Paul G., Zonder, Jeffrey A., Voorhees, Peter M., Kaufman, Jonathan L., Yee, Andrew J., Scott, Emma C., Torka, Pallawi, Libby, Edward, Reeves, Brandi, Wang, Michael L., Anderson, Larry D., Jr., Milner, Carter, Gasparetto, Cristina J., Agha, Mounzer, Khan, Abdullah, Hurd, David Duane, Avigan, David, Costello, Caitlin, Jakubowiak, Andrzej, Lonial, Sagar, Raje, Noopur, Medvedova, Eva, McCarthy, Philip L., Orlowski, Robert Z., Nadeem, Omar, Laubach, Jacob P., Pasquini, Marcelo C., Giralt, Sergio A., Masone, Kelly, Samur, Mehmet K., Perrot, Aurore, Moreau, Philippe, Avet-Loiseau, Herve, Weller, Edie A., Munshi, Nikhil C., and Anderson, Kenneth C.

Published
2022
Full Text
View/download PDF

22. Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.

Author

Martin, Thomas, Usmani, Saad Z., Berdeja, Jesus G., Agha, Mounzer, Cohen, Adam D., Hari, Parameswaran, Avigan, David, Deol, Abhinav, Htut, Myo, Lesokhin, Alexander, Munshi, Nikhil C., O'Donnell, Elizabeth, Stewart, A. Keith, Schecter, Jordan M., Goldberg, Jenna D., Jackson, Carolyn C., Yeh, Tzu-Min, Banerjee, Arnob, Allred, Alicia, and Zudaire, Enrique

Published
2023
Full Text
View/download PDF

23. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

Author

Lentzsch, Suzanne, O'Sullivan, Amy, Kennedy, Ryan C., Abbas, Mohammad, Dai, Lijun, Pregja, Silvana Lalo, Burt, Steve, Boyiadzis, Michael, Roodman, G. David, Mapara, Markus Y., Agha, Mounzer, Waas, John, Shuai, Yongli, Normolle, Daniel, and Zonder, Jeffrey A.

Published
2012
Full Text
View/download PDF

24. Biomarker Correlates of 3 Year Response in Cartitude-1: A Phase 1b/2 Open-Label Study of Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma

Author

Lin, Yi, Usmani, Saad Z., Berdeja, Jesús G, Jakubowiak, Andrzej, Agha, Mounzer E., Cohen, Adam D., Deol, Abhinav, Htut, Myo, Lesokhin, Alexander M., Munshi, Nikhil C., O'Donnell, Elizabeth, de Oca, Rocio Montes, Yeh, Tzu-min, Banerjee, Arnob, Madduri, Deepu, Zhao, Hao, del Corral, Christopher, Koneru, Mythili, Jackson, Carolyn C, Geng, Dong, Martin, Thomas, Jagannath, Sundar, and Wang, Feng

Published
2024
Full Text
View/download PDF

25. The Phase 2 Cartitude-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1–3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Author

Hillengass, Jens, Cohen, Adam D., Agha, Mounzer, Delforge, Michel, Kerre, Tessa, Roeloffzen, Wilfried, Einsele, Hermann, Goldschmidt, Hartmut, Weisel, Katja, Raab, Marc-Steffen, Scheid, Christoph, Anguille, Sébastien, Sonneveld, Pieter, Zweegman, Sonja, Schecter, Jordan M, De Braganca, Kevin C., Jackson, Carolyn C, Vlummens, Philip, Varsos, Helen, Corsale, Christina, Madduri, Deepu, Yeh, Tzu-min, Mistry, Pankaj, Roccia, Tito, Song, Qingxuan, Akram, Muhammad, Filho, Octavio Costa, Geng, Dong, Cohen, Yael C, and van de Donk, Niels W.C.J.

Published
2024
Full Text
View/download PDF

31. A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML.

Author

Lontos, Konstantinos, Tsagianni, Anastasia, Agha, Mounzer, Raptis, Anastasios, Hou, Jing-Zhou, Farah, Rafic, Redner, Robert L., Im, Annie, Dorritie, Kathleen A., Sehgal, Alison, Rossetti, James, Aggarwal, Nidhi, Saul, Melissa, Gooding, William, and Boyiadzis, Michael

Subjects
INDUCTION chemotherapy, CYTOGENETICS, ACUTE myeloid leukemia, NOMOGRAPHY (Mathematics), SOMATIC mutation
Abstract

Twenty patients (11%) had favorable risk cytogenetics, 108 patients (62%) had intermediate risk cytogenetics, and 47 patients (27%) had unfavorable risk cytogenetics. Prediction at AML diagnosis that a patient would not respond to standard induction chemotherapy would lead to the use of other therapies sparing the patient from the toxicities of treatments that prove to be ineffective. Genomic profiling has allowed major advances in unraveling the complex molecular signature of acute myeloid leukemia (AML) and has informed us of the prognosis and survival of AML patients [[1]]. [Extracted from the article]

Published
2022
Full Text
View/download PDF

32. Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Author

Houde, Christiane A., Khan, Abdullah, Jacobus, Susanna J., Hassoun, Hani, Anderson, Larry D., Jr., Merz, Lauren E., Zon, Rebecca L., Efebera, Yvonne, Buck, Tondre, Innis-Shelton, Racquel D., Hartley-Brown, Monique A, Lonial, Sagar, Campagnaro, Erica L., Voorhees, Peter M., Orlowski, Robert Z., Libby, Edward, Hurd, David Duane, Costello, Caitlin L., Raje, Noopur S., Medvedova, Eva, McCarthy, Philip L., Milner, Carter P., Gasparetto, Cristina, Agha, Mounzer E, Gowin, Krisstina, Kamble, Rammurti T., Jagannath, Sundar, Nathwani, Nitya, Alsina, Melissa, Giralt, Sergio A., Laubach, Jacob P., Nadeem, Omar, Ghobrial, Irene M., Mo, Clifton C., Samur, Mehmet K., Anderson, Kenneth C., Munshi, Nikhil C, and Richardson, Paul G.

Published
2023
Full Text
View/download PDF

36. P-275 CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma

Author

Jagannath, Sundar, Martin, Thomas, Usmani, Saad, Berdeja, Jesus, Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam, Deol, Abhinav, Htut, Myo, Lesokhin, Alexander, Munshi, Nikhil, O'Donnell, Elizabeth, Jackson, Carolyn, Yeh, Tzu-min, Banerjee, Arnob, Zudaire, Enrique, Madduri, Deepu, DelCorral, Christopher, Pacaud, Lida, and Lin, Yi

Published
2023
Full Text
View/download PDF

37. MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma

Author

Lin, Yi, Martin, Thomas, Usmani, Saad, Berdeja, Jesus, Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam, Deol, Abhinav, Htut, Myo, Lesokhin, Alexander, Munshi, Nikhil, O'Donnell, Elizabeth, Jackson, Carolyn, Yeh, Tzu-Min, Banerjee, Arnob, Zudaire, Enrique, Madduri, Deepu, delCorral, Christopher, Pacaud, Lida, and Jagannath, Sundar

Published
2023
Full Text
View/download PDF

38. POSTER: MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma

Author

Lin, Yi, Martin, Thomas, Usmani, Saad, Berdeja, Jesus, Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam, Deol, Abhinav, Htut, Myo, Lesokhin, Alexander, Munshi, Nikhil, O'Donnell, Elizabeth, Jackson, Carolyn, Yeh, Tzu-Min, Banerjee, Arnob, Zudaire, Enrique, Madduri, Deepu, del Corral, Christopher, Pacaud, Lida, and Jagannath, Sundar

Published
2023
Full Text
View/download PDF

39. Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS).

Author

Haidar, Ghady, Agha, Mounzer, Bilderback, Andrew, Lukanski, Amy, Linstrum, Kelsey, Troyan, Rachel, Rothenberger, Scott, McMahon, Deborah K, Crandall, Melissa D, Sobolewksi, Michele D, Enick, P Nathan, Jacobs, Jana L, Collins, Kevin, Klamar-Blain, Cynthia, Macatangay, Bernard J C, Parikh, Urvi M, Heaps, Amy, Coughenour, Lindsay, Schwartz, Marc B, and Dueker, Jeffrey M

Subjects
*HIV-positive persons, *IMMUNIZATION, *IMMUNOGLOBULINS, *COVID-19 vaccines, *IMMUNOCOMPROMISED patients, *PATIENTS, *AUTOIMMUNE diseases, *IMMUNOLOGICAL deficiency syndromes, *CANCER patients, *NEUTRALIZATION tests, *DESCRIPTIVE statistics, *HEMATOLOGIC malignancies, *LOGISTIC regression analysis, *LONGITUDINAL method, *TRANSPLANTATION of organs, tissues, etc.
Abstract

Background We studied humoral responses after coronavirus disease 2019 (COVID-19) vaccination across varying causes of immunodeficiency. Methods Prospective study of fully vaccinated immunocompromised adults (solid organ transplant [SOT], hematologic malignancy, solid cancers, autoimmune conditions, human immunodeficiency virus [HIV]) versus nonimmunocompromised healthcare workers (HCWs). The primary outcome was the proportion with a reactive test (seropositive) for immunoglobulin G to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain. Secondary outcomes were comparisons of antibody levels and their correlation with pseudovirus neutralization titers. Stepwise logistic regression was used to identify factors associated with seropositivity. Results A total of 1271 participants enrolled: 1099 immunocompromised and 172 HCW. Compared with HCW (92.4% seropositive), seropositivity was lower among participants with SOT (30.7%), hematological malignancies (50.0%), autoimmune conditions (79.1%), solid tumors (78.7%), and HIV (79.8%) (P <.01). Factors associated with poor seropositivity included age, greater immunosuppression, time since vaccination, anti-CD20 monoclonal antibodies, and vaccination with BNT162b2 (Pfizer) or adenovirus vector vaccines versus messenger RNA (mRNA)-1273 (Moderna). mRNA-1273 was associated with higher antibody levels than BNT162b2 or adenovirus vector vaccines after adjusting for time since vaccination, age, and underlying condition. Antibody levels were strongly correlated with pseudovirus neutralization titers (Spearman r  = 0.89, P  < .0001), but in seropositive participants with intermediate antibody levels, neutralization titers were significantly lower in immunocompromised individuals versus HCW. Conclusions Antibody responses to COVID-19 vaccines were lowest among SOT and anti-CD20 monoclonal recipients, and recipients of vaccines other than mRNA-1273. Among those with intermediate antibody levels, pseudovirus neutralization titers were lower in immunocompromised patients than HCWs. Additional SARS-CoV-2 preventive approaches are needed for immunocompromised persons, which may need to be tailored to the cause of immunodeficiency. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy.

Author

Lontos, Konstantinos, Tsagianni, Anastasia, Agha, Mounzer, Raptis, Anastasios, Hou, Jing-Zhou, Farah, Rafic, Redner, Robert L., Im, Annie, Dorritie, Kathleen A., Sehgal, Alison, Rossetti, James, Aggarwal, Nidhi, Saul, Melissa, Boyiadzis, Michael, and Bailey, Nathanael G.

Subjects
BONE marrow, BIOPSY, BONE marrow examination
Abstract

109 patients achieved a complete remission (CR), 5 patients achieved complete remission with incomplete hematologic recovery (CRi) and 2 patients achieved a morphologic leukemia-free state (MLFS). Acute myeloid leukemia (AML) is a life-threatening disease that requires urgent treatment. Of all patients, 23 (18%) patients had flow cytometric abnormalities and 105 (82%) patients did not. A similar approach is noted by Cheson et al. who recommend repeating the bone marrow biopsy if blasts are 5-20% in the bone marrow biopsy, as in some patients the increased blasts disappear in the next bone marrow biopsy [[4]]. [Extracted from the article]

Published
2023
Full Text
View/download PDF

42. 530 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) and Lenalidomide (R) Maintenance to Progression in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Author

Hassoun, Hani, Jacobus, Susanna J, Richardson, Paul G., Zonder, Jeffrey, Voorhees, Peter M., Kaufman, Jonathan L., Yee, Andrew J, Scott, Emma C, Torka, Pallawi, Libby, Edward N., Reeves, Brandi, Wang, Michael L., Anderson, Larry D., Jr., Milner, Carter, Gasparetto, Cristina, Agha, Mounzer, Khan, Dr. Abdullah, Hurd, David D, Avigan, David E., Costello, Caitlin, Jakubowiak, Andrzej, Lonial, Sagar, Raje, Noopur S, Medvedova, Eva, McCarthy, Dr. Philip L., Orlowski, Robert Z., Nadeem, Omar, Laubach, Jacob, Pasquini, Marcelo, Giralt, Sergio, Masone, Kelly, Samur, Mehmet, Perrot, Aurore, Moreau, Philippe, Avet-Loiseau, Hervé, Weller, Edie, Munshi, Nikhil C., and Anderson, Kenneth C.

Published
2023
Full Text
View/download PDF

47. Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Author

Van De Donk, Niels WCJ, Agha, Mounzer, Cohen, Adam D, Cohen, Yael C, Anguille, Sébastien, Kerre, Tessa, Roeloffzen, Wilfried W.H., Schecter, Jordan M, De Braganca, Kevin C, Jackson, Carolyn C, Varsos, Helen, Mistry, Pankaj, Roccia, Tito, Xu, Xiaoying, Li, Katherine, Zudaire, Enrique, Corsale, Christina, Akram, Muhammad, Geng, Dong, Pacaud, Lida, Sonneveld, Pieter, and Zweegman, Sonja

Published
2022
Full Text
View/download PDF

49. OAB-045: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel (cilta-cel) in lenalidomide-refractory multiple myeloma after 1–3 prior lines of therapy: CARTITUDE-2 Cohort A

Author

Cohen, Adam, Einsele, Hermann, Delforge, Michel, Hillengass, Jens, Goldschmidt, Hartmut, Weisel, Katja, Raab, Marc-Steffen, Scheid, Christof, Schecter, Jordan, De Braganca, Kevin, Varsos, Helen, Yeh, Tzu-min, Mistry, Pankaj, Roccia, Tito, Corsale, Christina, Akram, Muhammad, Pacaud, Lida, Nesheiwat, Tonia, Agha, Mounzer, and Cohen, Yael

Published
2022
Full Text
View/download PDF

50. OAB-043: Ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma and early relapse after initial therapy: biological correlative analyses and updated clinical results from CARTITUDE-2 Cohort B

Author

Agha, Mounzer, van de Donk, Niels W.C.J., Cohen, Adam, Cohen, Yael, Anguille, Sébastien, Kerre, Tessa, Roeloffzen, Wilfried, Schecter, Jordan, De Braganca, Kevin, Varsos, Helen, Mistry, Pankaj, Roccia, Tito, Zudaire, Enrique, Corsale, Christina, Akram, Muhammad, Geng, Dong, Nesheiwat, Tonia, Pacaud, Lida, Sonneveld, Pieter, and Zweegman, Sonja

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results